Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacmilimab (CX-072) Monotherapy and Combination in Advanced Solid Tumors or Lymphomas
NCT03013491Phase 2Terminated
- Sponsor
- CytomX
- Start
- Jan 2017
- Primary completion
- Oct 2020
- Modality
- Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of pacmilimab in solid tumor and lymphoma (7 arms), sponsored by CytomX. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jan 2017; status: terminated.
02
Drugs
pacmilimab
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03013491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013491.